A61P 31/663 (2006.01) A61P 29/00 (2006.01)

(21) International Application Number:
PCT/US2016/028807

(22) International Filing Date: 22 April 2016 (22.04.2016)

(25) Filing Language: English

(26) Publication Language: English


(72) Inventor: TABUTEAU, Herriot; 25 Broadway, 9th Floor, New York, NY 10004 (US).

(74) Agents: JOHNSON, Brent, A. et al; K&L Gates LLP, 1 Park Plaza, 12th Floor, Irvine, CA 92614 (US).


Published: with international search report (Art. 21(3))

(51) International Patent Classification:
A61P 31/663 (2006.01) A61P 29/00 (2006.01)

(34) Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
PHARMACODYNAMIC EFFECTS AFTER ORAL ADMINISTRATION OF
ZOLEDRONIC ACID OR RELATED COMPOUNDS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of United States Provisional Application No. 62/150,871, filed April 22, 2015, which is incorporated herein by reference in its entirety.

BACKGROUND

[0002] Bisphosphonate compounds are potent inhibitors of osteoclast activity, and are used clinically to treat bone-related conditions such as osteoporosis and Paget's disease of bone; and cancer-related conditions including multiple myeloma, and bone metastases from solid tumors. They generally have low oral bioavailability.

SUMMARY

[0003] It has been discovered that oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.

[0004] Some embodiments include a method of enhancing the oral bioavailability of zoledronic acid comprising orally administering a dosage form containing zoledronic acid in the disodium salt form.

[0005] Some embodiments include a dosage form comprising zoledronic acid in the disodium salt form, wherein the bioavailability, in a mammal, of zoledronic acid in the disodium salt form is greater than the bioavailability of zoledronic acid in the diacid form would be in the same dosage form.

[0006] Some embodiments include a dosage form comprising zoledronic acid in the disodium salt form, wherein the dosage form contains an amount of zoledronic acid in the disodium salt form that provides an area under the plasma concentration curve of zoledronic acid of about 4 ng•h/mL to about 2000 ng•h/mL to a human being to which the dosage form is administered.

[0007] Some embodiments include a dosage form comprising zoledronic acid in the disodium salt form, wherein the disodium salt form is present in a lower molar amount
than would be present if the zoledronic acid were in the diacid form; and wherein the zoledronic acid in the disodium salt form has an improved bioavailability as compared to the zoledronic acid in the diacid form to the extent that the lower molar amount of the disodium salt in the dosage form does not reduce the amount of zoledronic acid delivered to the plasma of a mammal.

[0008] Although an oral dosage form with enhanced bioavailability with respect to the bisphosphonate compound can be used, the treatment can also be effective using an oral dosage form that includes a bisphosphonate compound, such as zoledronic acid, wherein the bioavailability of the bisphosphonate is unenhanced, or is substantially unenhanced.

[0009] Some embodiments include a method of relieving inflammatory pain comprising administering an oral dosage form containing zoledronic acid to a mammal in need thereof, wherein the mammal experiences significant pain relief more than 3 hours after administration of the dosage form.

[0010] Some embodiments include a method of relieving pain associated with an arthritis comprising administering an oral dosage form containing zoledronic acid to a human being in need thereof.

[0011] Some embodiments include a method of treating complex regional pain syndrome comprising administering an oral dosage form containing zoledronic acid to a mammal in need thereof.

[0012] Some embodiments include an oral dosage form comprising zoledronic acid, wherein the oral bioavailability of zoledronic acid is substantially unenhanced. For example, in some embodiments, the oral bioavailability in the dosage form is about 0.01% to about 4%.

[0013] Some embodiments include a pharmaceutical product comprising more than one unit of an oral dosage form described herein. In some embodiments, each unit of the oral dosage form contains about 1 mg to about 50 mg of zoledronic acid.

[0014] Some embodiments include a method of relieving inflammatory pain comprising administering an oral dosage form containing zoledronic acid to a mammal in need thereof.

[0015] In some embodiments, the mammal receives a total monthly dose of zoledronic acid that is about 800 mg/m² or less.
In some embodiments, the dosage form contains about 10 mg/m² to about 20 mg/m² based upon the body surface area of the mammal.

Some embodiments include a method of relieving inflammatory pain comprising orally administering zoledronic acid to a mammal in need thereof.

In some embodiments, about 300 mg/m² to about 600 mg/m² of zoledronic acid is administered per month, based upon the body surface area of the mammal.

In some embodiments, about 500 mg/m² to about 600 mg/m² of zoledronic acid is administered per month, based upon the body surface area of the mammal.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 is a plot of pain compression thresholds in a rat model of inflammatory pain using three different doses of zoledronic acid. Measurements were taken at baseline (BL) and at various time points after dosing on the days indicated.

FIG. 2A is a graph depicting reversal of arthritis pain for two different doses of zoledronic acid in a rat model of arthritis pain.

FIG. 2B is a graph depicting pain thresholds for two different doses of zoledronic acid in a rat model of arthritis pain.

FIG. 3 is a graph summarizing the results for vehicle and zoledronic acid treated rats in a rat model of complex regional pain syndrome.

FIG. 4 depicts hindpaw pain thresholds for vehicle and zoledronic acid treated rats in a rat model of complex regional pain syndrome.

FIG. 5 depicts weight bearing for vehicle and zoledronic acid treated rats in a rat model of complex regional pain syndrome.

FIG. 6 depicts paw thickness change for vehicle and zoledronic acid treated rats in a rat model of complex regional pain syndrome.

FIG. 7 depicts the aqueous solubility of disodium zoledronate tetrahydrate as compared to the diacid form of zoledronic acid.
FIG. 8 depicts the plasma concentration of zoledronic acid in dogs over time after administration of 150 mg of the disodium salt form of zoledronic acid and the diacid form of zoledronic acid.

FIG. 9 depicts the compressibility of dosage forms containing zoledronic acid in the disodium salt form as compared to the diacid form.

DETAILED DESCRIPTION

Bisphosphonate compounds such as pamidronate or pamidronic acid, neridronate or neridronic acid, olpadronate or olpadronic acid, alendronate or alendronic acid, incadronate or incadronic acid, ibandronate or ibandronic acid, risedronate or risedronic acid, zoledronate or zoledronic acid, etidronate or etidronic acid, clodronate or clodronic acid, tiludronate or tiludronic acid, etc., may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including pain relief. This may be accomplished in many instances by administration of oral dosage forms. Generally, an oral dosage form comprising a bisphosphonate such as zoledronic acid is administered orally to a mammal, such as a human being, at least once, to treat a disease or condition, or to relieve pain.

The term "treating" or "treatment" broadly includes any kind of treatment activity, including the diagnosis, cure, mitigation, or prevention of disease in man or other animals, or any activity that otherwise affects the structure or any function of the body of man or other animals.

An oral dosage form of a bisphosphonate such as zoledronic acid may be used to treat, or provide relief of, any type of pain including, but not limited to, inflammatory pain, arthritis pain, complex regional pain syndrome, lumbosacral pain, musculoskeletal pain, neuropathic pain, chronic pain, cancer-related pain, acute pain, postoperative pain, etc. In some instances, pain relief may be palliative, or pain relief may be provided independent of improvement of the disease or condition or the underlying cause of the disease or condition. For example, although the underlying disease may not improve, or may continue to progress, an individual suffering from the disease may experience pain relief. In some embodiments, enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow
a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.

[0033] In some embodiments, the mammal being treated is not suffering from bone metastasis. In some embodiments, the mammal being treated is not suffering from cancer. In some embodiments, the mammal being treated is not suffering from osteoporosis.

[0034] For example, zoledronic acid or another bisphosphonate may be administered orally to relieve musculoskeletal pain including low back pain, and pain associated with rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, erosive osteoarthritis, sero-negative (non-rheumatoid) arthropathies, non-articular rheumatism, peri-articular disorders, axial spondyloarthritis including ankylosing spondylitis, Paget's disease, fibrous dysplasia, SAPHO syndrome, transient osteoarthritis of the hip, vertebral crush fractures, osteoporosis, etc. In some embodiments, enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.

[0035] In some embodiments, zoledronic acid or another bisphosphonate may also be administered orally to relieve neuropathic pain, including diabetic peripheral neuropathy, post-herpetic neuralgia, trigeminal neuralgia, monoradiculopathies, phantom limb pain, and central pain. Other causes of neuropathic pain include cancer-related pain, lumbar nerve root compression, spinal cord injury, post-stroke pain, central multiple sclerosis pain, HIV-associated neuropathy, and radio-therapy or chemo-therapy associated neuropathy. In some embodiments, enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.

[0036] In some embodiments, zoledronic acid or another bisphosphonate may be administered orally to relieve inflammatory pain including musculoskeletal pain, arthritis pain, and complex regional pain syndrome. In some embodiments, enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium
salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.

[0037] Examples of musculoskeletal pain include low back pain; and pain associated with vertebral crush fractures, fibrous dysplasia, osteogenesis imperfecta, Paget's disease of bone, transient osteoporosis, and transient osteoporosis of the hip.

[0038] Arthritis refers to inflammatory joint diseases that can be associated with pain. Examples of arthritis pain include pain associated with osteoarthritis, erosive osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, sero-negative (non-rheumatoid) arthropathies, non-articular rheumatism, peri-articular disorders, neuropathic arthropathies including Charcot's foot, axial spondylarthritis including ankylosing spondylitis, and SAPHO syndrome.

[0039] In some embodiments, a human being that is treated for arthritis by an oral dosage form of zoledronic acid has an age of about 10 years to about 90 years, about 20 years to about 80 years, about 30 years to about 75 years, about 40 years to about 70 years, about 1 year to about 16 years, or about 80 years to about 95 years.

[0040] In some embodiments, a human being that is treated for arthritis by an oral dosage form of zoledronic acid has suffered from the arthritis for at least 1 month, at least 2 months, at least 6 months, or at least 1 year.

[0041] In some embodiments, the arthritis affects a knee, an elbow, a wrist, a shoulder, or a hip.

[0042] In some embodiments, zoledronic acid or another bisphosphonate may be administered orally to relieve complex regional pain syndrome, such as complex regional pain syndrome type I (CRPS-I), complex regional pain syndrome type II (CRPS-II), CRPS-NOS, or another type of CRPS. CRPS is a type of inflammatory pain. CRPS can also have a neuropathic component.

[0043] Complex regional pain syndrome is a debilitating pain syndrome. It is characterized by severe pain in a limb accompanied by edema, and autonomic, motor and sensory changes.

[0044] With respect to use of oral zoledronic acid for relieving pain associated with an inflammatory condition, relief of pain can be short-term, e.g. for a period of hours after administration of the dosage form, and/or relief of pain can be long-term, e.g. lasting for
days, weeks, or even months after oral administration of zoledronic acid. In some embodiments, a mammal, such as a human being, experiences significant pain relief at least about 3 hours, at least about 6 hours, at least about 12 hours, at least about 24 hours, at least about 48 hours, at least about one week, at least about 2 weeks, or at least about 3 weeks after administration of an oral dosage form comprising zoledronic acid. In some embodiments, a mammal, such as a human being, experiences significant pain relief during at least part of the time from about 3 hours to about 2 weeks, about 3 hours to about 3 weeks, about 3 hours to about 24 hours, about 6 hours to about 2 weeks, or about 6 hours to about 24 hours, about 3 days to about 2 weeks, about 6 days to about 2 weeks, after administration of an oral dosage form comprising zoledronic acid.

[0045] With respect to the treatment of any condition recited herein, in some embodiments a first oral dosage form comprising zoledronic acid is administered and a second oral dosage form comprising oral zoledronic acid is administered. The timing of the administration of the two dosage forms may be such that, with respect to the first oral dosage form, the second oral dosage with respect to the first oral dosage form, the second oral dosage form is administered at $5 \times T_{\text{max}}$ or greater (e.g., if $T_{\text{max}}$ is 1 hour, at 5 hours or later), at least $10 \times T_{\text{max}}$ or greater, at least about $15 \times T_{\text{max}}$ or greater, at least about $20 \times T_{\text{max}}$ or greater, at least about $50 \times T_{\text{max}}$ or greater, or at least about $200 \times T_{\text{max}}$ or greater, wherein $T_{\text{max}}$ is the time of maximum plasma concentration for the first oral dosage form.

[0046] Some embodiments include treatment of a condition recited herein, such as inflammatory pain, arthritis, or complex regional pain syndrome, wherein the treatment comprises either: administering only one dosage form to a mammal to treat the condition, or administering a first dosage form to the mammal, followed by administering a second dosage form to the mammal. If two or more dosage forms are administered, the second oral dosage form is administered before the maximum pain relieving effect of the first oral dosage form is achieved, or before a peak in the pain relieving effect of the first oral dosage form is experienced by a mammal, receiving the dosage form. In some embodiments, the second oral dosage form is administered before an observable pain relieving effect is achieved. In some embodiments, the second dosage form is administered about 12 hours to about 60 days, about 24 hours to about 28 days, about
24 hours to about 7 days, about 24 hours to about 14 days, or about 24 hours to about 21 days, after the first dosage form is administered.

[0047] Some embodiments include treatment of a condition recited herein, such as inflammatory pain, arthritis, or complex regional pain syndrome, wherein the treatment comprises administering a first dosage form to the mammal, followed by administering a second dosage form to the mammal, wherein the second dosage form is administered after the maximum pain relieving effect of the first oral dosage form is achieved, and the second oral dosage form is administered while the mammal is still experiencing pain relief from the first oral dosage form, or while the pain relieving effect from the first oral dosage form is observable. In some embodiments, the second dosage form is administered about 12 hours to about 60 days, about 24 hours to about 28 days, about 24 hours to about 7 days, about 24 hours to about 14 days, or about 24 hours to about 21 days, after the first dosage form is administered.

[0048] Zoledronic acid or another bisphosphonate may also be administered orally to relieve cancer-related pain, including pain associated with multiple myeloma and bone metastases from solid tumors. In some embodiments, zoledronic acid is used to treat pain that is not cancer-related pain. For example, zoledronic acid may be used to treat pain that is not associated with multiple myeloma, bone metastasis from solid tumors, hypercalcemia of malignancy, giant cell tumor of bone, blood cancers or leukemias, or solid tumors or cancers. In some embodiments, enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.

[0049] In addition to relieving pain, oral administration of zoledronic acid or another bisphosphonate may also be useful to treat diseases or conditions that may or may not include a pain component. For example, zoledronic acid or another bisphosphonate may be useful to treat any of the pain conditions or types of conditions listed above, including treatment that does not simply relieve the pain of those conditions, and treatment that is carried out in such a way that the condition is treated without pain relief occurring. In addition to any pain relief zoledronic acid or another bisphosphonate may or may not provide, zoledronic acid or another bisphosphonates may be used to treat a disease or condition such as a metabolic disease or condition; an inflammatory disease
or condition, including an inflammatory disease or condition that is not associated with pain; a cancer disease or condition; a neurological disease or condition; etc. In some embodiments, enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.

[0050] In some embodiments, oral administration of zoledronic acid or another bisphosphonate may also be useful to treat complex regional pain syndrome, rheumatoid arthritis, osteoarthritis, erosive osteoarthritis, axial spondyloarthritis including ankylosing spondylitis, acute vertebral crush fracture, fibrous dysplasia, SAPHO syndrome, osteoporosis, transient osteoporosis, or transient osteoporosis of the hip. In some embodiments, enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.

[0051] In some embodiments, oral administration of zoledronic acid or another bisphosphonate may also be useful to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, Paget's disease of bone, giant cell tumor of bone, blood cancers or leukemias, or solid tumors or cancers. In some embodiments, enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.

[0052] Zoledronic acid has the structure shown below, and is also referred to as zoledronate.
Zoledronic acid

[0053] Unless otherwise indicated, any reference to a compound herein, such as zoledronic acid, by structure, name, or any other means, includes pharmaceutically acceptable salts, such as the disodium salt; alternate solid forms, such as polymorphs, solvates, hydrates, etc.; tautomers; or any other chemical species that may rapidly convert to a compound described herein under conditions in which the compounds are used as described herein.

[0054] In some embodiments, zoledronic acid is administered in a dosage form comprising a salt form, such as a salt of a dianion of zoledronic acid. In some embodiments, zoledronic acid is administered in a dosage form comprising a disodium salt form of zoledronic acid. In some embodiments, zoledronic acid is administered in a sodium salt form, such as a monosodium salt, a disodium salt, a trisodium salt, etc. In some circumstances, use of the disodium salt may be desirable. For example, the disodium salt is much more soluble in water than the diacid form. As a result, in some processes, the disodium salt can be easier to work with than the diacid form. Additionally, the sodium salt may be more bioavailable and/or more rapidly absorbed when taken orally as compared to the diacid form.

[0055] The oral bioavailability of zoledronic acid may be enhanced by orally administering the zoledronic acid in the disodium salt form. For example, the bioavailability of zoledronic acid may be improved by at least about 10%, at least about 20%, at least about 30%, at least about 50%, and/or up to about 100%, or up to about 200%, as compared to administration of zoledronic acid in the diacid form.

[0056] Because of the improved bioavailability of the disodium salt a dosage form may contain, or a mammal, such as a human being, may receive, on a molar basis, less of the disodium salt form of zoledronic acid than would otherwise be administered of the diacid form of zoledronic acid. For example, a dosage form may contain, or a mammal may receive, at least about 10 mole% less, at least about 20 mole% less, at least about 40 mole% less, at least about 50 mole% less, and/or up to about 90 mole% less or 95 mole% less, of the disodium salt form as compared the amount of the diacid form of zoledronic acid that would otherwise be administered, such as a molar amount that would be administered of zoledronic acid in the diacid form in order to achieve the same plasma levels of zoledronic acid.
In some embodiments, a dosage form contains, or a mammal (such as a human being) is administered, an amount of the disodium salt form, on a molar basis, that has a value of about \(0.8n_d\) to about \(1.2n_d\) or about \(0.9n_d\) to about \(1.1n_d\), wherein:

\[ n_d = \frac{b_a}{b_d}(n_a) \]

wherein \(b_a\) is the bioavailability of the diacid form, \(b_d\) is the bioavailability of the disodium salt form, and \(n_a\) is the number of moles of the diacid that would be administered in a dosage form containing the diacid form of zoledronic acid. For example, if the diacid form has a bioavailability \((b_a)\) of 0.01 and the disodium salt form has a bioavailability \((b_d)\) of 0.015, and a dosage form would normally contain 0.001 moles of the diacid, \(n_d\) would be \((0.01/0.015)(0.001)\) moles, or about 0.00067 moles. In some embodiments, the disodium salt is administered in an amount that has a value of about \(n_d\).

With respect to oral dosage forms comprising a reduced molar amount of the disodium salt of zoledronic acid as compared to the diacid form of zoledronic acid, in some embodiments, the bioavailability of the zoledronic acid in the disodium salt form is sufficiently high that, if the drug is administered to a mammal, at least as much zoledronic acid is present in the blood of the mammal as would be present if zoledronic acid were administered in the diacid form.

With respect to oral dosage forms comprising the disodium salt form of zoledronic acid, in some embodiments, the disodium salt form is present in a lower molar amount than would be present if the zoledronic acid were in the diacid form; and the zoledronic acid in the disodium salt form has an improved bioavailability as compared to the zoledronic acid in the diacid form to the extent that the lower molar amount of the disodium salt in the dosage form does not reduce the amount of zoledronic acid delivered to the plasma of a mammal.

In some embodiments, the zoledronic acid in the disodium salt form is present in an amount such that the oral dosage form provides an area under the plasma concentration curve of zoledronic acid of about 4 ng·h/mL to about 2000 ng·h/mL to the mammal each time the zoledronic acid in the disodium salt is administered.

In some embodiments, the zoledronic acid in the disodium salt form is present in an amount such that the oral dosage form provides an area under the plasma concentration curve of zoledronic acid of about 100 ng·h/mL to about 2000 ng·h/mL, about 100 ng·h/mL to about 1000 ng·h/mL, about 500 ng·h/mL to about 1000 ng·h/mL,
or about 500 ng•h/ml to about 700 ng•h/ml in the mammal to which the dosage form is administered. This amount may be suitable for administration of the oral dosage form about every 3 to 4 weeks.

[0062] In some embodiments, the zoledronic acid in the disodium salt form is present in an amount such that the oral dosage form provides an area under the plasma concentration curve of zoledronic acid of about 500 ng•h/ml to about 700 ng•h/ml, about 50 ng•h/ml to about 500 ng•h/ml, or about 100 ng•h/ml to about 200 ng•h/ml, in the mammal to which the dosage form is administered. This amount may be suitable for weekly administration of the oral dosage, or for administration of 3 to 5 individual dosages during a month. The individual dosages could be given at regular intervals, given during the first week, or at any other schedule that provides 3 to 5 dosages during the month.

[0063] In some embodiments, the zoledronic acid in the disodium salt form is present in an amount such that the oral dosage form provides an area under the plasma concentration curve of zoledronic acid of about 4 ng•h/ml to about 100 ng•h/ml, about 10 ng•h/ml to about 50 ng•h/ml, or about 10 ng•h/ml to about 30 ng•h/ml, in the mammal to which the dosage form is administered. This amount may be suitable for daily administration of the oral dosage form.

[0064] Oral administration of zoledronic acid, particularly oral administration of the disodium salt form of zoledronic acid, can result in more sustained plasma levels of the drug as compared to parenteral modes of administration, such intravenous or subcutaneous. For example, the amount of zoledronic acid in the plasma can be significantly higher for oral administration of the disodium salt about 24 hours or 48 hours, or longer, after administration. In some embodiments, oral zoledronic acid has a 24 hour sustained plasma level factor of about 1 or higher, such as about 1 to about 10, about 1 to about 5, about 3 to about 5, or about 3 to about 4. In some embodiments, an orally administered dosage form of zoledronic acid has a 24 hour sustained plasma level factor or a 48 hour sustained plasma level factor that is higher, such as at least 1.2 times, at least about 2 times, at least about 5 times, about 1.2 times to about 20 times, about 2 times to about 15 times, about 5 times to about 10 times, or about 8 times to about 15 times that of intravenously administered zoledronic acid. A "sustained plasma level factor," \( p_f \), is determined by the equation:

\[
p_f = 1000 \frac{C_t}{C_{\text{max}}} \]
wherein \( C_{\text{max}} \) is the maximum plasma concentration of zoledronic acid after it is administered and \( C_t \) is the plasma concentration of zoledronic acid at the time of interest, such as 24 hours. For parenteral administration, the \( C_{\text{max}} \) can be about the \( C_0 \), or the concentration right after injection of the entire amount of the drug into the body. Sustained plasma level factors can also be obtained for other times, such as 48 hours, by using the plasma concentration of zoledronic acid for \( C_t \) in the equation above. For example, if the maximum plasma level of zoledronic acid after administration is 1000 ng/mL and the plasma level of zoledronic acid at 24 hours is 1 ng/mL, the 24 hour sustained plasma level factor is 1.

[0065] In some embodiments, the disodium salt form of zoledronic acid provides an enhancement to bioavailability, as compared to the diacid form of zoledronic acid, which adds to any enhancement to bioavailability provided by any bioavailability-enhancing agents in the dosage form. In some embodiments, the disodium salt form of zoledronic acid provides an enhancement to bioavailability, as compared to the diacid form of zoledronic acid, which is greater than any enhancement to bioavailability provided by any bioavailability-enhancing agents in the dosage form. In some embodiments, the disodium salt form of zoledronic acid may be administered in a dosage form that is substantially free of bioavailability-enhancing agents.

[0066] The C-terminal telopeptide (CTX) is one of the products from type I collagen degradation by osteoclasts during bone resorption. Thus, CTX serum levels may be used as a biomarker to indicate and monitor bone breakdown, resorption, and loss. In some embodiments, zoledronic acid and other bisphosphonates may be used to inhibit osteoclast activity and/or lower CTX serum levels, for example, by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 70%, at least about 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, at least 100%, between about 60%-70%, between about 70%-80%, between about 80%-90%, between about 85%-95%, between about 85%-90%, between about 90%-95%, or any other reduction in osteoclast activity or CTX serum levels in a range bounded by, or between, any of these values.

[0067] In some embodiments, a dosage form comprising a disodium salt of zoledronic acid is a solid.
In some embodiments, a dosage form comprising a disodium salt of zoledronic acid is used to treat an inflammatory condition.

In some embodiments, a dosage form comprising a disodium salt of zoledronic acid is used to treat arthritis.

In some embodiments, a dosage form comprising a disodium salt of zoledronic acid is used to treat complex regional pain syndrome.

In some embodiments, zoledronic acid is in a form that has an aqueous solubility, meaning the solubility in water, greater than 1% (w/v), about 5% (w/v) to about 50% (w/v), about 5% (w/v) to about 20% (w/v), about 10% (w/v) to about 15% (w/v), or about 12% (w/v) to about 13% (w/v).

The disodium salt form of zoledronic acid can be more compressible than the diacid form of zoledronic acid. This can make it easier for a dosage form to have a desired hardness. It can also make it easier to increase the drug load, so that a smaller tablet can be given for a given dosage strength. In some embodiments, a solid dosage form of zoledronic acid, such as the diacid form of zoledronic acid or the disodium salt form of zoledronic acid, can have a hardness of about 5 kPa to about 20 kPa or about 5 kPa to about 14 kPa.

Zoledronic acid or another bisphosphonate may be combined with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice as described, for example, in Remington’s Pharmaceutical Sciences, 2005, the disclosure of which is hereby incorporated herein by reference, in its entirety. The relative proportions of active ingredient and carrier may be determined, for example, by the solubility and chemical nature of the compounds, chosen route of administration and standard pharmaceutical practice.

Zoledronic acid or another bisphosphonate may be administered by any means that may result in the contact of the active agent(s) with the desired site or site(s) of action in the body of a patient. The compounds may be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. For example, they may be administered as the sole active agents in a pharmaceutical composition, or they can be used in combination with other therapeutically active ingredients.
Zoledronic acid or another bisphosphonate may be administered to a human patient in a variety of forms adapted to the chosen route of administration, e.g., orally, rectally, or parenterally. Parenteral administration in this respect includes, but is not limited to, administration by the following routes: pulmonary, intrathecal, intravenous, intramuscular, subcutaneous, intraocular, intrasynovial, transepithelial including transdermal, sublingual and buccal; topically; nasal inhalation via insufflation; and rectal systemic.

The effective amount of zoledronic acid or another bisphosphonate will vary depending on various factors known to the treating physicians, such as the severity of the condition to be treated, route of administration, formulation and dosage forms, physical characteristics of the bisphosphonate compound used, and age, weight and response of the individual patients.

The amount of zoledronic acid or another bisphosphonate in a therapeutic composition may vary. For example, some liquid compositions may comprise about 0.0001% (w/v) to about 50% (w/v), about 0.01% (w/v) to about 20% (w/v), about 0.01% to about 10% (w/v), about 0.001% (w/v) to about 1% (w/v), about 0.1% (w/v) to about 0.5% (w/v), about 1% (w/v) to about 3% (w/v), about 3% (w/v) to about 5% (w/v), about 5% (w/v) to about 7% (w/v), about 7% (w/v) to about 10% (w/v), about 10% (w/v) to about 15% (w/v), about 15% (w/v) to about 20% (w/v), about 20% (w/v) to about 30% (w/v), about 30% (w/v) to about 40% (w/v), or about 40% (w/v) to about 50% (w/v) of zoledronic acid.

Some solid compositions may comprise at least about 5% (w/w), at least about 10% (w/w), at least about 20% (w/w), at least about 50% (w/w), at least about 70% (w/w), at least about 80%, about 10% (w/w) to about 30% (w/w), about 10% (w/w) to about 20% (w/w), about 20% (w/w) to about 30% (w/w), about 30% (w/w) to about 50% (w/w), about 30% (w/w) to about 40% (w/w), about 40% (w/w) to about 50% (w/w), about 50% (w/w) to about 80% (w/w), about 50% (w/w) to about 60% (w/w), about 70% (w/w) to about 75% (w/w), about 70% (w/w) to about 80% (w/w), or about 80% (w/w) to about 90% (w/w) of zoledronic acid.

Any suitable amount of zoledronic acid may be used. Some solid or liquid oral dosage forms, or units of oral dosage forms (referred to collectively herein as "oral dosage form(s)") may contain about 0.005 mg to about 20 mg, about 0.1 mg to about 10 mg, about 0.5 mg to about 10 mg, about 0.2 mg to about 5 mg, about 1 mg to about 500
mg, about 1 mg to about 50 mg, about 10 mg to about 250 mg, about 100 mg to about 300 mg, about 20 mg to about 200 mg, about 20 mg to about 150 mg, about 30 mg to about 100 mg, about 1 mg to about 1,000 mg, about 10 mg to about 50 mg, about 10 mg to about 300 mg, about 10 mg to about 150 mg, about 10 mg to about 100 mg, about 40 mg to about 150 mg, about 10 mg to about 600 mg, about 40 mg to about 600 mg, about 40 mg to about 2000 mg, about 40 mg to about 800 mg, about 25 mg to about 800 mg, about 30 mg to about 800 mg, about 10 mg to about 500 mg, about 50 mg to about 150 mg, about 50 mg, about 100 mg, about 50 mg to about 500 mg, about 100 mg to about 2000 mg, about 300 mg to about 1500 mg, about 200 mg to about 1000 mg, about 100 mg to about 500 mg, or about 150 mg of zoledronic acid, or any amount of zoledronic in a range bounded by, or between, any of these values. In some embodiments, the oral zoledronic acid is administered daily, weekly, monthly, every two or three months, once a year, or twice a year.

[0080] In some embodiments, an oral dosage form may contain about 10 mg/m² to about 20 mg/m², about 15 mg/m² to about 20 mg/m², about 18 mg/m², about 80 mg/m² to about 150 mg/m², about 90 mg/m² to about 150 mg/m², about 100 mg/m² to about 150 mg/m² of zoledronic acid, or any amount of zoledronic in a range bounded by, or between, any of these values. All dosage ranges or amounts expressed in mg/m² are based upon the body surface area of the mammal.

[0081] In some embodiments the daily oral dose of zoledronic acid is about 0.005 mg to about 20 mg, about 0.1 mg to about 10 mg, about 0.5 mg to about 10 mg, about 0.2 mg to about 5 mg, or any amount of zoledronic acid in a range bounded by, or between, any of these values. In some embodiments, the daily oral dose of zoledronic acid is less than about 35 mg/m², less than about 30 mg/m², less than about 25 mg/m², about 1 mg/m² to about 35 mg/m², about 1 mg/m² to about 30 mg/m², about 1.5 mg/m² to about 25 mg/m², about 1.8 mg/m² to about 20 mg/m², about 10 mg/m² to about 20 mg/m², about 10 mg/m² to about 30 mg/m², about 15 mg/m² to about 20 mg/m², about 18 mg/m², or any amount of zoledronic acid in a range bounded by, or between, any of these values.

[0082] In some embodiments the weekly oral dose of zoledronic acid is about 1 mg to about 1000 mg, about 1 mg to about 500 mg, about 10 mg to about 250 mg, about 100 mg to about 300 mg, about 10 mg to about 100 mg, about 10 mg to about 150 mg, about 10 mg to about 100 mg, about 10 mg to about 300 mg, about 20 mg to about 150
mg, or about 30 mg to about 100 mg. In some embodiments, the weekly oral dose of zoledronic acid is less than about 250 mg/m², less than about 200 mg/m², less than about 175 mg/m², about 6 mg/m² to about 250 mg/m², about 10 mg/m² to about 210 mg/m², about 10 mg/m² to about 170 mg/m², about 4 mg/m² to about 140 mg/m², about 100 mg/m² to about 140 mg/m², about 126 mg/m², or any amount of zoledronic acid in a range bounded by, or between, any of these values. The weekly oral dose may be given as a single dose, given once during the week, or may be given in 2, 3, 4, 5, 6, or 7 individual doses during the week.

[0083] In some embodiments, the monthly dose of zoledronic acid, or the amount of zoledronic acid that is administered over a period of a month, is about 5000 mg or less, about 4000 mg or less, about 3000 mg or less, about 2000 mg or less, about 1000 mg or less, about 700 mg or less, about 600 mg or less, about 1 mg to about 4000 mg, about 1 mg to about 1000 mg, about 10 mg to about 1000 mg, about 50 mg to about 1000 mg, about 10 mg to about 600 mg, about 40 mg to about 600 mg, about 50 mg to about 600 mg, or about 100 mg to about 600 mg, about 40 mg to about 2000 mg, about 40 mg to about 800 mg, about 50 mg to about 800 mg, or about 100 mg to about 800 mg, about 40 mg to about 1000 mg, about 50 mg to about 1000 mg, or about 100 mg to about 1000 mg, or any monthly dose in a range bounded by, or between, any of these values. In some embodiments, the monthly oral dose of zoledronic acid is less than about 1000 mg/m², less than about 800 mg/m², less than about 600 mg/m², about 10 mg/m² to about 1000 mg/m², about 50 mg/m² to about 800 mg/m², about 70 mg/m² to about 700 mg/m², about 100 mg/m² to about 700 mg/m², about 100 mg/m² to about 600 mg/m², about 50 mg/m² to about 200 mg/m², about 300 mg/m² to about 600 mg/m², about 450 mg/m² to about 600 mg/m², about 300 mg/m² to about 1000 mg/m², about 400 mg/m² to about 1000 mg/m², about 50 mg/m² to about 1000 mg/m², about 400 mg/m² to about 700 mg/m², about 500 mg/m² to about 600 mg/m², about 540 mg/m², or any amount of zoledronic acid in a range bounded by, or between, any of these values. A monthly dose may be given as a single dose, or as two or more individual doses administered during the month. In some embodiments, the monthly dose is administered in 2 or 3 weekly doses. In some embodiments, the monthly dose is administered in 4 or 5 weekly doses. In some embodiments, the monthly dose is administered in 28 to 31 daily doses. In some embodiments, the monthly dose is administered in 5 to 10 individual doses during the month. The monthly dose may be administered for only 1 month, or may be repeatedly administered for 2 or more months.
The oral zoledronic acid, or disodium salt thereof, may be administered in combination with about 0.1 mg to about 10 mg of zoledronic acid, or a salt thereof, administered parenterally, such as intravenously. In some embodiments, about 50 mg, about 100 mg, or about 150 mg of the disodium salt of zoledronic acid is administered orally in combination with 1 mg parenteral, such as intravenous, zoledronic acid. In some embodiments the parenteral dose of zoledronic acid is about 0.25 mg to about 25 mg, about 0.25 mg to about 10 mg, or about 0.5 mg to about 7.5 mg.

With respect to oral administration of zoledronic acid, or another bisphosphonate, for the treatment of pain associated with inflammation, arthritis, CRPS, or any other condition recited herein, it may helpful if the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage, (other than any water required to swallow the oral dosage form) for at least about 1 hour, at least about 2 hours, at least about 4 hours, at least about 6 hours, at least about 8 hours, at least about 10 hours, or at least about 12 hours before the zoledronic acid is administered. It may also be helpful if the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least about 30 minutes, at least about 1 hour, at least about 2 hours, at least about 3 hours, or at least about 4 hours after the zoledronic acid is administered. In some embodiments, a human being to which the zoledronic acid is administered avoids lying down, or remains upright or sits upright, for at least about 30 minutes or about 1 hour after receiving a dosage form containing zoledronic acid. Avoiding food or beverage before or after oral administration of zoledronic acid can improve the bioavailability of the zoledronic acid.

The oral bioavailability of zoledronic acid in a dosage form can vary. Some dosage forms may have ingredients added to enhance the bioavailability. However, bioavailability enhancement is not necessary for an oral dosage form to be effective. In some embodiments, the dosage form is substantially free of bioavailability-enhancing agents, such as amino acids or large quantities (e.g. at least about 5%, 10%, 20%, 50%, 70%, or more) of carboxylic acid salts. In some embodiments, an oral dosage form may have an oral bioavailability of zoledronic acid of about 0.01% to about 10%, about 0.1% to about 7%, about 0.1% to about 5%, etc. Without ingredients or other methods to enhance bioavailability, zoledronic acid typically has a low bioavailability in an oral dosage form. In some embodiments, the oral bioavailability of zoledronic acid is unenhanced or substantially unenhanced. For example, the oral bioavailability of
zoledronic acid can be about 0.01% to about 5%, about 0.01% to about 4%, about 0.1% to about 3%, about 0.1% to about 2%, about 0.2% to about 2%, about 0.2% to about 1.5%, about 0.3% to about 1.5%, about 0.3% to about 1%, about 0.1% to about 0.5%, about 0.3% to about 0.5%, about 0.5% to about 1%, about 0.6% to about 0.7%, about 0.7% to about 0.8%, about 0.8% to about 0.9%, about 0.9% to about 1%, about 1% to about 1.1%, about 1.1% to about 1.2%, about 1.2% to about 1.3%, about 1.3% to about 1.4%, about 1.4% to about 1.5%, about 1.5% to about 1.6%, about 1.6% to about 1.8%, or about 1.8% to about 2%.

[0088] One embodiment is a pharmaceutical composition comprising zoledronic acid wherein the oral bioavailability of zoledronic acid in the dosage form is from about 0.01% to about 10%.

[0087] In some embodiments, the oral bioavailability of zoledronic acid in the dosage form is about 0.01% to about 5%.

[0088] In some embodiments, the oral bioavailability of zoledronic acid in the dosage form is about 0.1% to about 7%.

[0089] In some embodiments, the oral bioavailability of zoledronic acid in the dosage form is about 0.1% to about 5%.

[0090] In some embodiments, the oral bioavailability of zoledronic acid in the dosage form is about 0.1% to about 3%.

[0091] In some embodiments, the oral bioavailability of zoledronic acid in the dosage form is about 0.1% to about 2%.

[0092] In some embodiments, the oral bioavailability of zoledronic acid in the dosage form is about 0.2% to about 2%.

[0093] In some embodiments, the oral bioavailability of zoledronic acid in the dosage form is about 0.2% to about 1.5%.

[0094] In some embodiments, the oral bioavailability of zoledronic acid in the dosage form is about 0.3% to about 1.5%.

[0095] In some embodiments, the oral bioavailability of zoledronic acid in the dosage form is about 0.3% to about 1.0%.
in some embodiments, an oral dosage form comprises about 10 mg to about
300 mg of zoledronic acid, and is administered daily for about 2 to about 15 consecutive
days. This regimen may be repeated once monthly, once every two months, once every
three months, once every four months, once every five months, once every six months,
one yearly, or once every two years.

In some embodiments, an oral dosage form comprises about 10 mg to about
150 mg or about 10 mg to about 100 mg of zoledronic acid, and is administered daily for
about 2 to about 15 consecutive days. This regimen may be repeated once monthly,
one every two months, once every three months, once every four months, once every
five months, once every six months, once yearly, or once every two years.

In some embodiments, an oral dosage form comprises about 10 mg to about
150 mg or about 10 mg to about 100 mg of zoledronic acid, and is administered daily for
about 5 to about 10 consecutive days. This regimen may be repeated once monthly,
one every two months, once every three months, once every four months, once every
five months, once every six months, once yearly, or once every two years.

In some embodiments, an oral dosage form comprises about 40 mg to about
150 mg of zoledronic acid, and is administered daily for about 5 to about 10 consecutive
days. This regimen may be repeated once monthly, once every two months, once every
three months, once every four months, once every five months, once every six months,
one yearly, or once every two years.

In some embodiments, the oral zoledronic acid may be administered as one
dose of about 100 mg to about 2000 mg. In some embodiments, the oral zoledronic acid
may be administered as one dose of about 300 mg to about 1500 mg. In some
embodiments, the oral zoledronic acid may be administered as one dose of about 200
mg to about 1000 mg. The dose of zoledronic acid may be administered in a single or
divided dose.

Zoledronic acid may be formulated for oral administration, for example, with
an inert diluent or with an edible carrier, or it may be enclosed in hard or soft shell gelatin
capsules, compressed into tablets, or incorporated directly with the food of the diet. For
oral therapeutic administration, the active compound may be incorporated with an
excipient and used in the form of ingestible tablets, buccal tablets, coated tablets,
troches, capsules, elixirs, dispersions, suspensions, solutions, syrups, wafers, patches, and the like.

[0102] Tablets, troches, pills, capsules and the like may also contain one or more of the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient, such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin; or a flavoring agent such as peppermint, oil of wintergreen or cherry flavoring. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coating, for instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor. It may be desirable for material in a dosage form or pharmaceutical composition to be pharmaceutically pure and substantially non-toxic in the amounts employed.

[0103] Some compositions or dosage forms may be a liquid, or may comprise a solid phase dispersed in a liquid.

[0104] Zoledronic acid may be formulated for parental or intraperitoneal administration. Solutions of the active compounds as free acids or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. A dispersion can also have an oil dispersed within, or dispersed in, glycerol, liquid polyethylene glycols, and mixtures thereof. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

[0105] In some embodiments, an oral dosage form may comprise a silicified microcrystalline cellulose such as PROSOLOV®. For example, about 20% (wt/wt) to about 70% (wt/wt), about 10% (wt/wt) to about 20% (wt/wt), about 20% (wt/wt) to about 40% (wt/wt), about 25% (wt/wt) to about 30% (wt/wt), about 40% (wt/wt) to about 50% (wt/wt), or about 45% (wt/wt) to about 50% (wt/wt) silicified microcrystalline cellulose may be present in an oral dosage form or a unit of an oral dosage form.

[0106] In some embodiments, an oral dosage form may comprise a crosslinked polyvinylpyrrolidone such as crospovidone. For example, about 1% (wt/wt) to about
10% (wt/wt), about 1% (wt/wt) to about 5% (wt/wt), or about 1% (wt/wt) to about 3% (wt/wt) crosslinked polyvinylpyrrolidone may be present in an oral dosage form or a unit of an oral dosage form.

[0107] In some embodiments, an oral dosage form may comprise a fumed silica such as AEROSIL®. For example, about 0.1% (wt/wt) to about 10% (wt/wt), about 0.1% (wt/wt) to about 1% (wt/wt), or about 0.4% (wt/wt) to about 0.6% (wt/wt) fumed silica may be present in an oral dosage form or a unit of an oral dosage form.

[0108] In some embodiments, an oral dosage form may comprise magnesium stearate. For example, about 0.1% (wt/wt) to about 10% (wt/wt), about 0.1% (wt/wt) to about 1% (wt/wt), or about 0.4% (wt/wt) to about 0.6% (wt/wt) magnesium stearate may be present in an oral dosage form or a unit of an oral dosage form.

[0109] An oral dosage form comprising zoledronic acid or another bisphosphonate may be included in a pharmaceutical product comprising more than one unit of the oral dosage form.

[0110] A pharmaceutical product containing oral dosage forms for daily use can contain 28, 29, 30, or 31 units of the oral dosage form for a monthly supply. An approximately 6 week daily supply can contain 40 to 45 units of the oral dosage form. An approximately 3 month daily supply can contain 85 to 95 units of the oral dosage form. An approximately six-month daily supply can contain 170 to 200 units of the oral dosage form. An approximately one year daily supply can contain 350 to 380 units of the oral dosage form.

[0111] A pharmaceutical product containing oral dosage forms for weekly use can contain 4 or 5 units of the oral dosage form for a monthly supply. An approximately 2 month weekly supply can contain 8 or 9 units of the oral dosage form. An approximately 6 week weekly supply can contain about 6 units of the oral dosage form. An approximately 3 month weekly supply can contain 12, 13 or 14 units of the oral dosage form. An approximately six-month weekly supply can contain 22 to 30 units of the oral dosage form. An approximately one year weekly supply can contain 45 to 60 units of the oral dosage form.

[0112] A pharmaceutical product may accommodate other dosing regimes. For example, a pharmaceutical product may comprise 5 to 10 units of the oral dosage form, wherein each unit of the oral dosage form contains about 40 mg to about 150 mg of zoledronic acid. Some pharmaceutical products may comprise 1 to 10 units of the oral
dosage form, wherein the product contains about 200 mg to about 2000 mg of zoledronic acid. For such a product, each unit of the oral dosage form may be taken daily for 1 to 10 days or 5 to 10 days during a month, such as at the beginning of a month.

[0113] Some oral dosage forms comprising zoledronic acid or a salt thereof may have enteric coatings or film coatings.

[0114] In the examples below, zoledronic acid was administered in the disodium salt form as disodium zoledronate tetrahydrate. No bioavailability enhancing agents were used in the test compositions.

**Example 1. Effect of Orally Administered Zoledronic Acid in Rat Model of Inflammatory Pain**

**Method:**

[0115] The effect of orally administered zoledronic acid on inflammatory pain was examined using the rat complete Freund's adjuvant (CFA) model. Inflammatory pain was induced by injection of 100% CFA in a 75 μL volume into the left hind paws of SPRAGUE-DAWLEY® rats on day 0, followed by assessments on days 1-3. Animals were orally administered vehicle (control), zoledronic acid 18 mg/m² (or 3 mg/kg), zoledronic acid 120 mg/m² (or 20 mg/kg), or zoledronic acid 900 mg/m² (or 150 mg/kg) daily on days 1-3. Drug was dissolved in distilled water and prepared fresh daily. Animals were fasted prior to dosing. Under current FDA guidelines for extrapolating starting dosages from animals to humans, dosages expressed in mg/m² are considered equivalent between mammalian species. Thus, for example, 18 mg/m² in a rat is considered equivalent to 18 mg/m² in a human being, while 3 mg/kg in a rat may not be equivalent to 3 mg/kg in a human being.

[0116] Values for inflammatory pain (mechanical hyperalgesia) in the vehicle and drug-treated animals were obtained on day 0 prior to CFA injection, and at baseline and post-treatment on days 1-3. Pain was assessed using a digital Randall-Selitto device (dRS; IITC Life Sciences, Woodland Hills, CA). Animals were placed in a restraint sling that suspended the animal, leaving the hind limbs available for testing. Paw compression threshold was measured by applying increasing pressure to the plantar surface of the hind paw with a dome-shaped tip placed between the 3rd and 4th metatarsus. Pressure was applied gradually over approximately 10 seconds. Measurements were taken from
the first observed nocifensive behavior of vocalization, struggle or withdrawal. A cut-off value of 300 g was used to prevent injury to the animal.

[0117] Reversal of inflammatory pain was calculated according to the formula:

\[
\% \text{ reversal} = \frac{\text{Post-treatment} - \text{Post-CFA baseline}}{\text{Pre-CFA baseline} - \text{Post-CFA baseline}} \times 100.
\]

[0118] The experiment was carried out using 9-10 animals per group.

Results:

[0119] Oral administration of zoledronic acid significantly improved inflammatory pain thresholds compared to vehicle. Pain threshold measurements taken at various times are shown in FIG. 1. Paw compression thresholds in the 18 mg/m² group were higher than for vehicle during the entire measurement period after 30 minutes from the start of treatment. On day three, paw compression thresholds for both the 18 mg/m² and 900 mg/m² groups were greater than for vehicle. An improvement in pain threshold of 49% and 83% from baseline was observed for the 18 mg/m² and the 900 mg/m² groups respectively.

[0120] Orally administered zoledronic acid produced a 29% reversal of inflammatory pain at the 18 mg/m², and a 48% reversal at the 900 mg/m² dose. This magnitude of effect is comparable to that obtained with clinical doses of commercially available NSAIDs when tested in a similar model of inflammatory pain. Under current FDA guidelines, the reference body surface area of a human adult is 1.62 m². Thus, a daily dose of 18 mg/m² corresponds to a monthly dose of about 500-560 mg/m² or a human dose of about 800-900 mg.

[0121] Surprisingly, the two higher doses resulted in thresholds that were lower than vehicle on the first two days of dosing. The 120 mg/m² group was approximately equal or inferior to vehicle at all time points during the assessment period. While the 900 mg/m² group showed effectiveness on day 3, this result was accompanied by significant toxicity necessitating euthanization of all the animals in this group two days after cessation of dosing.

Example 2. Effect of Orally Administered Zoledronic Acid in Rat Model of Arthritis Pain

Method:
The effect of orally administered zoledronic acid on arthritis pain was examined in the rat complete Freund's adjuvant (CFA) model of arthritis pain. In this model, injection of 100% complete Freund's adjuvant (CFA) in a 75 µL volume into the left hind paws is followed by a 10-14 day period to allow for the development of arthritis pain. Animals were orally administered vehicle (control), zoledronic acid 54 mg/m² (or 9 mg/kg), or zoledronic acid 360 mg/m² (or 60 mg/kg), divided in three equal daily doses on the first three days post CFA injection. Drug was dissolved in distilled water and prepared fresh daily. Animals were fasted prior to dosing.

Arthritis pain (mechanical hyperalgesia) in the vehicle and drug-treated animals was evaluated on day 14 post CFA injection using a digital Randall-Selitto device (dRS; IITC Life Sciences, Woodland Hills, CA). Animals were placed in a restraint sling that suspended the animal, leaving the hind limbs available for testing. Paw compression threshold was measured by applying increasing pressure to the plantar surface of the hind paw with a dome-shaped tip placed between the 3rd and 4th metatarsals. Pressure was applied gradually over approximately 10 seconds. Measurements were taken from the first observed nocifensive behavior of vocalization, struggle, or withdrawal. A cut-off value of 300 g was used to prevent injury to the animal.

Reversal of arthritis pain in the ipsilateral (CFA-injected) paw was calculated according to the formula:

\[
\text{% reversal} = \frac{(\text{ipsilateral drug threshold} - \text{ipsilateral vehicle threshold})}{(\text{contralateral vehicle threshold} - \text{ipsilateral vehicle threshold})} \times 100.
\]

The experiment was carried out using 7-10 animals per group.

Results:

Oral administration of zoledronic acid significantly improved arthritis pain thresholds compared to vehicle. As shown in FIGS. 2A and 2B, orally administered zoledronic acid produced a dose-dependent reversal of arthritis pain. A reversal of 33% was observed in the 54 mg/m² group, and reversal of 54% was observed in the 360 mg/m² group. Under current FDA guidelines, the reference body surface area of a human adult is 1.62 m². Thus, 54 mg/m² in a rat is equivalent to an implied human dose of about 87 mg, and 360 mg/m² in a rat is equivalent to an implied human dose of about 583 mg.
Example 3. Treatment of Complex Regional Pain Syndrome with Orally Administered Zoledronic Acid.

[0127] The effect of orally administered zoledronic acid was examined in the rat tibia fracture model of complex regional pain syndrome (CRPS). CRPS was induced in the rats by fracturing the right distal tibias of the animals and casting the fractured hindpaws for 4 weeks, as described in Guo TZ et al. (Pain. 2004;108:95-107). This animal model has been shown to replicate the inciting trauma, natural history, signs, symptoms, and pathologic changes observed in human CRPS patients (Kingery WS et al., Pain. 2003;104:75-84).

[0128] Animals were orally administered either vehicle (control) or zoledronic acid, in a dosage of 18 mg/m²/day (3 mg/kg/day) for 28 days, starting on the day of fracture and casting. Drug was dissolved in distilled water and administered by gavage. Animals were fasted for 4 hours before and 2 hours after dosing. At the end of the 28-day period, casts were removed, and on the following day, the rats were tested for hindpaw pain, edema, and warmth.

Pain assessments

[0129] Pain was assessed by measuring hyperalgesia, and weight bearing.

[0130] To measure hyperalgesia, an up-down von Frey testing paradigm was used. Rats were placed in a clear plastic cylinder (20 cm in diameter) with a wire mesh bottom and allowed to acclimate for 15 minutes. The paw was tested with one of a series of eight von Frey hairs ranging in stiffness from 0.41 g to 15.14 g. The von Frey hair was applied against the hindpaw plantar skin at approximately midsole, taking care to avoid the tori pads. The fiber was pushed until it slightly bowed and then it was jiggled in that position for 6 seconds. Stimuli were presented at an interval of several seconds. Hindpaw withdrawal from the fiber was considered a positive response. The initial fiber presentation was 2.1 g and the fibers were presented according to the up-down method of Dixon to generate six responses in the immediate vicinity of the 50% threshold. Stimuli were presented at an interval of several seconds.

[0131] An incapacitance device (IITC Inc. Life Science, Woodland, CA, USA) was used to measure hindpaw weight bearing, a postural effect of pain. The rats were manually held in a vertical position over the apparatus with the hindpaws resting on separate metal scale plates and the entire weight of the rat was supported on the
hindpaws. The duration of each measurement was 6 seconds and 10 consecutive measurements were taken at 60-second intervals. Eight readings (excluding the highest and lowest ones) were averaged to calculate the bilateral hindpaw weight-bearing values. Weight bearing data were analyzed as the ratio between right (fracture) and left hindpaw weight bearing values ((2R/(R+L)) *100%).

**Edema assessment**

[0132] A laser sensor technique was used to determine the dorsal-ventral thickness of the hindpaw. Before baseline testing the bilateral hindpaws were tattooed with a 2 to 3 mm spot on the dorsal skin over the midpoint of the third metatarsal. For laser measurements each rat was briefly anesthetized with isoflurane and then held vertically so the hindpaw rested on a table top below the laser. The paw was gently held flat on the table with a small metal rod applied to the top of the ankle joint. Using optical triangulation, a laser with a distance measuring sensor was used to determine the distance to the table top and to the top of the hindpaw at the tattoo site and the difference was used to calculate the dorsal-ventral paw thickness. The measurement sensor device used in these experiments (4381 Precicura, Limab, Goteborg, Sweden) has a measurement range of 200 mm with a 0.01 mm resolution.

**Hindpaw temperature measurement**

[0133] The temperature of the hindpaw was measured using a fine wire thermocouple (Omega, Stanford, CT, USA) applied to the paw skin. Six sites were tested per hindpaw. The six measurements for each hindpaw were averaged for the mean temperature.

**Results**

[0134] As illustrated in FIG. 3, treatment with orally administered zoledronic acid reversed pain, restored weight bearing, and prevented edema as compared to vehicle treated animals.

[0135] As illustrated in FIG. 4, von Frey pain thresholds for the right (fracture) hindpaw were reduced by 72% versus the contralateral (normal) hindpaw in vehicle treated animals. Zoledronate treatment reversed fracture induced pain by 77% as compared to vehicle treatment.

[0136] As illustrated in FIG. 5, reduction in weight bearing, a postural effect of pain, was significantly higher in the vehicle treated group as compared to the zoledronic acid
treated group. Weight bearing on the fracture hindlimb was reduced to 55% of normal in
the vehicle treated group. Zoledronate treatment significantly restored hindlimb weight
bearing as compared to vehicle treatment (86% of normal).

[0137] As illustrated in FIG. 6, the expected increase in hindpaw thickness was
greater in the vehicle treated group as compared to the zoledronic acid treated group,
reflecting the development of edema. Zoledronate treatment reduced hindpaw edema by
60% versus vehicle treatment.

[0138] Zoledronic acid reduced hindpaw warmth by 5% versus vehicle treatment.

[0139] The daily dose in the above experiment was 18 mg/m$^2$/day. Under current
FDA guidelines, the reference body surface area of a human adult is 1.62 m$^2$. Thus, a
daily dose of 18 mg/m$^2$ corresponds to a monthly dose of about 500-560 mg/m$^2$ or a
human dose of about 800-900 mg.

Example 4. Solubility of Disodium Salt of Zoledronic Acid

[0140] The aqueous solubility of zoledronic acid and disodium zoledronate
tetrahydrate was determined. One gram of the test compound was measured in to a
beaker. Demineralized water (pH 5.5) was then added in small increments to the test
compound, and sonication was applied to the mixture. The procedure was continued
until complete dissolution was achieved. Full dissolution was determined to have been
reached when a clear solution was present with no visible material. The volume of water
required to reach full dissolution was used to calculate a solubility value expressed in
grams per 100 mL. The procedure was performed for each compound.

Results

[0141] As shown in FIG. 7, the aqueous solubility of disodium zoledronate
tetrahydrate is approximately 50 times that of zoledronic acid. Disodium zoledronate
tetrahydrate has a solubility of 12.5 g/100 mL compared to only 0.25 g/100 mL for
zoledronic acid.

Example 5. Bioavailability of Orally Administered Zoledronic Acid and Disodium
Zoledronate

[0142] Tablets were manufactured containing either pure zoledronic acid or the
disodium salt of zoledronic acid (disodium zoledronate tetrahydrate). Both types of
tablets contained 50 mg of zoledronic acid equivalent per tablet. Identical excipients
were used in both types of tablets, with amounts adjusted to account for the difference in molecular weights between the acid and the disodium salt.

[0143] Beagle dogs were orally administered tablets containing 150 mg zoledronic acid equivalent either in the form of disodium zoledronate (Group 1) or pure zoledronic acid (Group 2). Each animal was given three 50 mg equivalent tablets (150 mg total), which were administered together. The animal’s oral cavity was wetted with water before placing the tablets on the back of the animal's tongue. Animals were fasted before and after dosing. Animals were 6 to 9 months of age and weighed 6 to 10 kg on the day of dosing. There were three dogs per group.

[0144] Serial blood samples were collected from each animal by venipuncture of the jugular vein at various points after dosing for measurement of plasma concentrations of zoledronic acid. Blood samples were collected into chilled tubes containing K₂EDTA as the anticoagulant. Samples were then centrifuged at approximately 3000 rpm at +4°C for 10 minutes for plasma derivation. Plasma concentrations of zoledronic acid were measured using an LC/MS/MS method.

Results

[0145] The average plasma concentrations of zoledronic acid for each group of dogs is summarized in Table 1 and illustrated in Figure 8. Detectable plasma levels of zoledronic acid were observed for the entire 48 hours that they were measured.

Table 1
Zoledronic Acid plasma concentrations in beagle dogs

<table>
<thead>
<tr>
<th>Group 1 (N=3)</th>
<th>Time (hour)</th>
<th>Plasma concentration (ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disodium Zoledronate Tablets (150 mg acid equivalent)</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>0.25</td>
<td>1193.97</td>
</tr>
<tr>
<td></td>
<td>0.5</td>
<td>1852.12</td>
</tr>
<tr>
<td></td>
<td>0.75</td>
<td>1776.51</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>1626.56</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>640.57</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>136.93</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>53.11</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>26.97</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>13.74</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>6.78</td>
</tr>
</tbody>
</table>
Table 1

<table>
<thead>
<tr>
<th>Group 2 (N=3)</th>
<th>Zoledronic Acid Tablets (150 mg acid equivalent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>0.25</td>
<td>390.92</td>
</tr>
<tr>
<td>0.5</td>
<td>846.19</td>
</tr>
<tr>
<td>0.75</td>
<td>819.15</td>
</tr>
<tr>
<td>1</td>
<td>831.77</td>
</tr>
<tr>
<td>2</td>
<td>477.76</td>
</tr>
<tr>
<td>4</td>
<td>90.11</td>
</tr>
<tr>
<td>6</td>
<td>28.22</td>
</tr>
<tr>
<td>8</td>
<td>15.10</td>
</tr>
<tr>
<td>12</td>
<td>6.13</td>
</tr>
<tr>
<td>24</td>
<td>3.18</td>
</tr>
<tr>
<td>48</td>
<td>1.84</td>
</tr>
</tbody>
</table>

[0146] Disodium zoledronate produced significantly higher plasma levels zoledronic acid than pure zoledronic acid, indicating improved oral absorption with the salt form. Measured using peak plasma concentrations (C<sub>max</sub>), the disodium salt resulted in a 119% actual and 74% weight-adjusted increase in bioavailability as compared to pure zoledronic acid. Measured using area under the plasma concentration curve (AUC<sub>0-</sub>), bioavailability was 84% and 46% greater with the disodium salt than with pure zoledronic acid, on an actual and weight-adjusted basis respectively. The average AUC<sub>0-</sub> for the disodium salt was 4073 ng•hr/ml and the average AUC<sub>0-</sub> for the diacid was 2217 ng•hr/ml. The AUC<sub>0-</sub> was found to be dose proportional. Thus, for beagle dogs similar to those tested, about 3 mg to about 4 mg of the disodium salt would be expected to result in an AUC<sub>0-</sub> of about 100 ng•hr/ml, and about 7 mg to about 8 mg of the disodium salt would be expected to result in an AUC<sub>0-</sub> of about 200 ng•hr/ml.

Example 6. Hardness of Tablets Comprising Zoledronic Acid in the Free Acid and Disodium Salt Forms

[0147] Tablets were prepared by blending zoledronic acid, either in the form of the free acid or the disodium salt, with identical excipients. For dosage forms with a greater amount of active, the amount of the excipients was reduced proportionally to keep the weight of the tablet at about 100 mg. After blending, the ingredients were compressed at varying pressures, followed by a film coating. The resulting tablets were then tested.
for hardness using a Dr. Schleuniger Pharmatron 8M Tablet Hardness Tester. The results are shown in Table 2 and FIG. 9.

Table 2

<table>
<thead>
<tr>
<th>Compression Force (psi)</th>
<th>Hardness (kPa)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diacid 50 mg</td>
</tr>
<tr>
<td>800</td>
<td>4.0</td>
</tr>
<tr>
<td>1100</td>
<td>6.1</td>
</tr>
<tr>
<td>1500</td>
<td>7.7</td>
</tr>
<tr>
<td>2000</td>
<td>8.7</td>
</tr>
<tr>
<td>2400</td>
<td>8.7</td>
</tr>
<tr>
<td>3000</td>
<td>11.4</td>
</tr>
<tr>
<td>4400</td>
<td>12.5</td>
</tr>
<tr>
<td>5500</td>
<td>12.8</td>
</tr>
<tr>
<td>6100</td>
<td>13.0</td>
</tr>
</tbody>
</table>

[0148] The following embodiments are specifically contemplated:

**Embodiment 1.** A method of relieving inflammatory pain comprising administering an oral dosage form containing zoledronic acid to a mammal in need thereof, wherein the mammal receives a total monthly dose of zoledronic acid that is about 800 mg/m² or less based upon the body surface area of the mammal.

**Embodiment 2.** The method of embodiment 1, wherein the mammal is a human being that receives a total monthly dose of zoledronic acid that is about 30 mg/m² to about 700 mg/m².

**Embodiment 3.** The method of embodiment 2, wherein the total monthly dose is administered in 4 or 5 weekly doses.

**Embodiment 4.** The method of embodiment 2, wherein the total monthly dose is administered in 28 to 31 daily doses.

**Embodiment 5.** The method of embodiment 2, wherein the total monthly dose is administered in 5 to 10 individual doses during the month.

**Embodiment 6.** The method of embodiment 1, wherein the mammal is a human being that receives a total weekly dose of zoledronic acid that is about 10 mg to about 300 mg.

**Embodiment 7.** The method of embodiment 6, wherein the total weekly dose is a single dose, administered once a week.
Embodiment 8. The method of embodiment 6, wherein the total weekly dose is administered in 2 to 7 individual doses during the week.

Embodiment 9. The method of embodiment 1, wherein the mammal is a human being that receives a total weekly dose of zoledronic acid that is about 10 mg to about 150 mg.

Embodiment 10. The method of any preceding embodiment, wherein the mammal experiences significant pain relief more than 3 hours after administration of the dosage form.

Embodiment 11. The method of embodiment 10, wherein the mammal experiences significant pain relief during at least a part of a time from about 3 hours to about 24 hours after administration of the dosage form.

Embodiment 12. The method of embodiment 10, wherein the mammal experiences significant pain relief during at least a part of a time from about 3 hours to about 3 weeks after administration of the dosage form.

Embodiment 13. A method of relieving inflammatory pain comprising administering an oral dosage form containing zoledronic acid to a mammal in need thereof, wherein the oral dosage form contains about 10 mg/m² to about 20 mg/m² of zoledronic acid based upon the body surface area of the mammal.

Embodiment 14. The method of embodiment 13, wherein the oral dosage form contains about 15 mg/m² to about 20 mg/m² of zoledronic acid based upon the body surface area of the mammal.

Embodiment 15. A method of relieving inflammatory pain comprising orally administering to a mammal in need thereof, about 300 mg/m² to about 600 mg/m² of zoledronic acid per month to the mammal, based upon the body surface area of the mammal.

Embodiment 16. The method of embodiment 15, comprising orally administering about 450 mg/m² to about 600 mg/m² of zoledronic acid per month to the mammal, based upon the body surface area of the mammal.

Embodiment 17. The method of any preceding embodiment, wherein the mammal is not suffering from bone metastasis.

Embodiment 18. The method of any preceding embodiment, wherein the mammal is not suffering from cancer.

Embodiment 19. The method of any preceding embodiment, wherein the zoledronic acid is administered as a salt of a dianion of zoledronic acid.
Embodiment 20. A method of relieving pain associated with an arthritis comprising administering an oral dosage form containing zoledronic acid to a human being in need thereof.

Embodiment 21. The method of embodiment 20, wherein the human being receives a total monthly dose of zoledronic acid that is about 40 mg to about 2000 mg.

Embodiment 22. The method of embodiment 21, wherein the total monthly dose is administered in 4 or 5 weekly doses.

Embodiment 23. The method of embodiment 21, wherein the total monthly dose is administered in 28 to 31 daily doses.

Embodiment 24. The method of embodiment 21, wherein the total monthly dose is administered in 5 to 10 individual doses during the month.

Embodiment 25. The method of embodiment 20, wherein the human being receives a total weekly dose of zoledronic acid that is about 100 mg to about 300 mg.

Embodiment 26. The method of embodiment 25, wherein the total weekly dose is a single dose, administered once a week.

Embodiment 27. The method of embodiment 25, wherein the total weekly dose is administered in 2 to 7 individual doses during the week.

Embodiment 28. The method of embodiment 20, wherein the human being receives a total weekly dose of zoledronic acid that is about 10 mg to about 100 mg.

Embodiment 29. The method of any of embodiments 20-28, wherein the human being experiences significant pain relief more than 3 hours after administration of the dosage form.

Embodiment 30. The method of embodiment 29, wherein the human being experiences significant pain relief during at least a part of a time from about 3 hours to about 24 hours after administration of the dosage form.

Embodiment 31. The method of embodiment 29, wherein the human being experiences significant pain relief during at least a part of a time from about 3 hours to about 3 weeks after administration of the dosage form.

Embodiment 32. The method of any of embodiments 20-31, wherein the dosage form contains about 10 mg/m² to about 20 mg/m² of zoledronic acid based upon the body surface area of the human being.
**Embodiment 33.** The method of embodiment 32, wherein the dosage form contains about 15 mg/m² to about 20 mg/m² of zoledronic acid based upon the body surface area of the human being.

**Embodiment 34.** The method of any of embodiments 20-33, wherein about 50 mg/m² to about 200 mg/m² of zoledronic acid is orally administered per month, based upon the body surface area of the human being.

**Embodiment 35.** The method of any of embodiments 20-31, wherein the dosage form contains about 80 mg/m² to about 150 mg/m² of zoledronic acid based upon the body surface area of the human being.

**Embodiment 36.** The method of embodiment 35, wherein about 300 mg/m² to about 1000 mg/m² of zoledronic acid is orally administered per month, based upon the body surface area of the human being.

**Embodiment 37.** The method of any of embodiments 20-36, wherein the human being is not suffering from bone metastasis.

**Embodiment 38.** The method of any of embodiments 20-37, wherein the human being is not suffering from cancer.

**Embodiment 39.** The method of any preceding embodiment, wherein the zoledronic acid is in the disodium salt form.

**Embodiment 40.** An oral dosage form comprising zoledronic acid, wherein the oral bioavailability of zoledronic acid in the dosage form is about 0.01% to about 4%.

**Embodiment 41.** The oral dosage form of embodiment 40, wherein the oral dosage form contains about 10 mg to about 300 mg of zoledronic acid.

**Embodiment 42.** The oral dosage form of embodiment 40, wherein the oral dosage form contains about 10 mg to about 50 mg of zoledronic acid.

**Embodiment 43.** The oral dosage form of any of embodiments 40-42, wherein the oral bioavailability of zoledronic acid in the dosage form is about 0.1% to about 2%.

**Embodiment 44.** A pharmaceutical product comprising more than one unit of an oral dosage form of embodiment 40.

**Embodiment 45.** The pharmaceutical product of embodiment 44, wherein each unit of the oral dosage form contains about 1 mg to about 50 mg of zoledronic acid.

**Embodiment 46.** The pharmaceutical product of embodiment 45, comprising 28, 29, 30, or 31 units of the oral dosage form, for a total of about 28 mg to about 1600 mg of zoledronic acid be administered in about 1 month.
Embodiment 47. The pharmaceutical product of embodiment 45, comprising 85 to 95 units of the oral dosage form, for a total of about 85 mg to about 4800 mg of zoledronic acid to be administered in about 3 months.

Embodiment 48. The pharmaceutical product of embodiment 45, comprising 170 to 200 units of the oral dosage form, for a total of about 170 mg to about 10,000 mg of zoledronic acid to be administered in about 6 months.

Embodiment 49. The pharmaceutical product of embodiment 45, comprising 350 to 380 units of the oral dosage form, for a total of about 350 mg to about 19,000 mg of zoledronic acid to be administered in about 1 year.

Embodiment 50. The pharmaceutical product of embodiment 44, wherein each unit of the oral dosage form contains about 10 mg to about 300 mg.

Embodiment 51. The pharmaceutical product of embodiment 50, comprising 4 or 5 units of the oral dosage form, for a total of about 40 mg to about 1500 mg of zoledronic acid to be administered within a period of about 1 month.

Embodiment 52. The pharmaceutical product of embodiment 50, comprising 8 or 9 units of the oral dosage form, for a total of about 80 mg to about 2700 mg of zoledronic acid to be administered in about 2 months.

Embodiment 53. The pharmaceutical product of embodiment 50, comprising 12, 13 or 14 units of the oral dosage form, for a total of about 120 mg to about 4200 mg of zoledronic acid to be administered in about 3 months.

Embodiment 54. The pharmaceutical product of embodiment 50, comprising 22 to 30 units of the oral dosage form, for a total of about 220 mg to about 9000 mg of zoledronic acid to be administered in about 8 months.

Embodiment 55. The pharmaceutical product of embodiment 50, comprising 45 to 60 units of the oral dosage form, for a total of about 450 mg to about 18000 mg of zoledronic acid to be administered in about 1 year.

Embodiment 58. The oral dosage form of any preceding embodiment, wherein the zoledronic acid is in a form that has an aqueous solubility greater than 1% (w/v).
Embodiment 59. The oral dosage form of any preceding embodiment, wherein the zoledronic acid is in a form that has an aqueous solubility of about 5% (w/v) to about 50% (w/v).

Embodiment 80. An oral dosage form comprising zoledronic acid and an excipient, wherein the zoledronic acid is in a form that has an aqueous solubility greater than 1% (w/v).

Embodiment 61. The oral dosage form of embodiment 80, wherein the zoledronic acid is in a form that has an aqueous solubility of about 5% (w/v) to about 50% (w/v).

**Embodiment 62.** A method of treating complex regional pain syndrome comprising administering an oral dosage form containing zoledronic acid to a mammal in need thereof.

**Embodiment 63.** The method of embodiment 62, wherein the mammal is a human being that receives an amount of zoledronic acid that is about 30 mg/m$^2$ to about 700 mg/m$^2$ in a period of one month or less.

**Embodiment 64.** The method of embodiment 63, wherein 4 or 5 weekly doses are administered in a period of one month or less.

**Embodiment 65.** The method of embodiment 63, wherein 28 to 31 daily doses are administered in a period of one month or less.

**Embodiment 66.** The method of embodiment 63, wherein 5 to 10 individual doses are administered during a period of one month or less.

**Embodiment 67.** The method of embodiment 63, wherein about 30 mg/m$^2$ to about 700 mg/m$^2$ of zoledronic acid is administered during only one month.

**Embodiment 68.** The method of embodiment 63, wherein about 30 mg/m$^2$ to about 700 mg/m$^2$ of zoledronic acid is administered in a period of one month or less for 2 or more consecutive months.

**Embodiment 69.** The method of embodiment 62, wherein the mammal receives about 10 mg/m$^2$ to about 30 mg/m$^2$ of zoledronic acid daily.

**Embodiment 70.** The method of embodiment 62, wherein the mammal is a human being that receives a total weekly dose of zoledronic acid that is about 10 mg to about 300 mg.

**Embodiment 71.** The method of embodiment 70, wherein the total weekly dose is a single dose, administered once a week.

**Embodiment 72.** The method of embodiment 70, wherein the total weekly dose is administered in 2 to 7 individual doses during the week.
**Embodiment 73.** The method of any of embodiments 62-72, wherein the complex regional pain syndrome is complex regional pain syndrome type I.

**Embodiment 74.** The method of any of embodiments 62-72, wherein the complex regional pain syndrome is complex regional pain syndrome type II.

**Embodiment 75.** The method of any preceding embodiment, wherein the zoledronic acid is in a salt form.

**Embodiment 76.** The method of any of embodiments 62-75, wherein the dosage form contains about 10 mg/m² to about 20 mg/m² of zoledronic acid based upon the body surface area of the mammal.

**Embodiment 77.** The method of embodiment 76, wherein the dosage form contains about 15 mg/m² to about 20 mg/m² of zoledronic acid based upon the body surface area of the mammal.

**Embodiment 78.** A method of treating complex regional pain syndrome, comprising administering pamidronic acid to a human being in need thereof.

**Embodiment 79.** A method of treating complex regional pain syndrome, comprising administering neridronic acid to a human being in need thereof.

**Embodiment 80.** A method of treating complex regional pain syndrome, comprising administering olpadronic acid to a human being in need thereof.

**Embodiment 81.** A method of treating complex regional pain syndrome, comprising administering alendronic acid to a human being in need thereof.

**Embodiment 82.** A method of treating complex regional pain syndrome, comprising administering incadronic acid to a human being in need thereof.

**Embodiment 83.** A method of treating complex regional pain syndrome, comprising administering ibandronic acid to a human being in need thereof.

**Embodiment 84.** A method of treating complex regional pain syndrome, comprising administering risedronic acid to a human being in need thereof.

**Embodiment 85.** A method of treating pain, comprising administering pamidronic acid to a human being in need thereof.

**Embodiment 86.** A method of treating pain, comprising administering neridronic acid to a human being in need thereof.
Embodiment 87. A method of treating pain, comprising administering olpadronic acid to a human being in need thereof.

Embodiment 88. A method of treating pain, comprising administering alendronic acid to a human being in need thereof.

Embodiment 89. A method of treating pain, comprising administering incadronic acid to a human being in need thereof.

Embodiment 90. A method of treating pain, comprising administering ibandronic acid to a human being in need thereof.

Embodiment 91. A method of treating pain, comprising administering risedronic acid to a human being in need thereof.

Embodiment 92. A method of treating arthritis pain, comprising administering pamidronic acid to a human being in need thereof.

Embodiment 93. A method of treating arthritis pain, comprising administering neridronic acid to a human being in need thereof.

Embodiment 94. A method of treating arthritis pain, comprising administering olpadronic acid to a human being in need thereof.

Embodiment 95. A method of treating arthritis pain, comprising administering alendronic acid to a human being in need thereof.

Embodiment 96. A method of treating arthritis pain, comprising administering incadronic acid to a human being in need thereof.

Embodiment 97. A method of treating arthritis pain, comprising administering ibandronic acid to a human being in need thereof.

Embodiment 98. A method of treating arthritis pain, comprising administering risedronic acid to a human being in need thereof.

Embodiment 99. A method of treating inflammatory pain, comprising administering pamidronic acid to a human being in need thereof.

Embodiment 100. A method of treating inflammatory pain, comprising administering neridronic acid to a human being in need thereof.
Embodiment 101. A method of treating inflammatory pain, comprising administering olpadronic acid to a human being in need thereof.

Embodiment 102. A method of treating inflammatory pain, comprising administering alendronic acid to a human being in need thereof.

Embodiment 103. A method of treating inflammatory pain, comprising administering incadronic acid to a human being in need thereof.

Embodiment 104. A method of treating inflammatory pain, comprising administering ibandronic acid to a human being in need thereof.

Embodiment 105. A method of treating inflammatory pain, comprising administering risedronic acid to a human being in need thereof.

Embodiment 106. A method of treating complex regional pain syndrome, comprising administering etidronic acid to a human being in need thereof.

Embodiment 107. A method of treating pain, comprising administering etidronic acid to a human being in need thereof.

Embodiment 108. A method of treating arthritis pain, comprising administering etidronic acid to a human being in need thereof.

Embodiment 109. A method of treating inflammatory pain, comprising administering etidronic acid to a human being in need thereof.

Embodiment 110. A method of treating complex regional pain syndrome, comprising administering clodronic acid to a human being in need thereof.

Embodiment 111. A method of treating pain, comprising administering clodronic acid to a human being in need thereof.

Embodiment 112. A method of treating arthritis pain, comprising administering clodronic acid to a human being in need thereof.

Embodiment 113. A method of treating inflammatory pain, comprising administering clodronic acid to a human being in need thereof.

Embodiment 114. A method of treating complex regional pain syndrome, comprising administering tiludronic acid to a human being in need thereof.
Embodiment 115. A method of treating pain, comprising administering tiludronic acid to a human being in need thereof.

Embodiment 116. A method of treating arthritis pain, comprising administering tiludronic acid to a human being in need thereof.

Embodiment 117. A method of treating inflammatory pain, comprising administering tiludronic acid to a human being in need thereof.

Embodiment 118. The method of any of embodiments 78-117, wherein the active compound is orally administered.

Embodiment 119. The method of any of embodiments 78-117, wherein the active compound is parenterally administered.

Embodiment 120. A method of enhancing the oral bioavailability of zoledronic acid comprising orally administering a dosage form containing zoledronic acid in the disodium salt form.

Embodiment 121. The method of embodiment 120, wherein the zoledronic acid in the disodium salt form provides an enhancement to bioavailability, as compared to zoledronic acid in the diacid form, which adds to any enhancement to bioavailability provided by any bioavailability-enhancing agents in the dosage form.

Embodiment 122. The method of embodiment 120, wherein the dosage form is substantially free of bioavailability-enhancing agents.

Embodiment 123. The method of embodiment 120, wherein the zoledronic acid in the disodium salt form is administered to a mammal in an amount that provides an area under the plasma concentration curve of zoledronic acid of about 4 ng•h/ml_ to about 2000 ng•h/ml_ to the mammal each time the zoledronic acid in the disodium salt is administered.

Embodiment 124. The method of embodiment 123, wherein the zoledronic acid in the disodium salt form is administered at an interval of about 3 to about 4 weeks in an amount that provides an area under the plasma concentration curve of zoledronic acid of about 100 ng•h/ml_ to about 2000 ng•h/ml_ to the mammal each time the zoledronic acid in the disodium salt form is administered.

Embodiment 125. The method of embodiment 123, wherein the zoledronic acid in the disodium salt form is administered weekly, or 3 to 5 times in a month, in an amount
that provides an area under the plasma concentration curve of zoledronic acid of about 20 ng•h/ml to about 700 ng•h/ml to the mammal each time the zoledronic acid in the disodium salt form is administered.

**Embodiment 126.** The method of embodiment 123, wherein the zoledronic acid in the disodium salt form is administered daily in an amount that provides an area under the plasma concentration curve of zoledronic acid of about 4 ng•h/ml to about 100 ng•h/ml to the mammal each time the zoledronic acid in the disodium salt form is administered.

**Embodiment 127.** The method of embodiment 120, wherein the dosage form is a solid.

**Embodiment 128.** The method of embodiment 120, 121, 122, 123, 124, 125, 126, or 127, wherein the bioavailability of zoledronic acid is improved by at least about 20% as compared to administration of zoledronic acid in the diacid form.

**Embodiment 129.** The method of embodiment 120, 121, 122, 123, 124, 125, 126, 127, or 128, further comprising administering, on a molar basis, less of the zoledronic acid in the disodium salt form than would be administered of zoledronic acid in the diacid form in order to achieve the same plasma levels of zoledronic acid.

**Embodiment 130.** The method of embodiment 129, wherein at least about 10 mole% less of the disodium salt form is administered as compared the amount of zoledronic acid in the diacid form that would be administered in order to achieve the same plasma levels of zoledronic acid.

**Embodiment 131.** The method of embodiment 129, wherein the disodium salt form is administered in an amount, on a molar basis, that has a value of about 0.8n_d to about 1.2n_d, wherein:

\[ n_d = \left( \frac{b_d}{b_a} \right) n_a \]

wherein \( b_a \) is the bioavailability of the diacid form, \( b_d \) is the bioavailability of the disodium salt form, and \( n_a \) is the number of moles of zoledronic acid in the diacid form that would be administered in order to achieve the same plasma levels of zoledronic acid.

**Embodiment 132.** The method of embodiment 131, wherein the disodium salt is administered in an amount that has a value of about \( n_d \).
Embodiment 133. The method of any of embodiments 120-132, wherein the zoledronic acid is used to treat an inflammatory condition.

Embodiment 134. The method of embodiment 133, wherein the zoledronic acid is used to treat arthritis.

Embodiment 135. The method of embodiment 133, wherein the zoledronic acid is used to treat complex regional pain syndrome.

Embodiment 136. The method of any of embodiments 1-39, 62-77, and 120-135, wherein:

a first oral dosage form is administered; and

a second oral dosage form is administered;

wherein, with respect to the first oral dosage form, the second oral dosage form is administered at 10 x $T_{max}$ or greater, wherein $T_{max}$ is the time of maximum plasma concentration for the first oral dosage form.

Embodiment 137. A dosage form comprising zoledronic acid in the disodium salt form, wherein the bioavailability, in a mammal, of zoledronic acid in the disodium salt form is greater than the bioavailability of zoledronic acid in the diacid form would be in the same dosage form.

Embodiment 138. A dosage form comprising zoledronic acid in the disodium salt form, wherein the dosage form contains an amount of zoledronic acid in the disodium salt form that provides an area under the plasma concentration curve of zoledronic acid of about 4 ng•h/ml to about 2000 ng•h/ml to a human being to which the dosage form is administered.

Embodiment 139. The dosage form of embodiment 138, wherein the dosage form contains an amount of zoledronic acid in the disodium salt form that provides an area under the plasma concentration curve of zoledronic acid of about 100 ng•h/ml to about 2000 ng•h/ml to a human being to which the dosage form is administered.

Embodiment 140. The dosage form of embodiment 138, wherein the dosage form contains an amount of zoledronic acid in the disodium salt form that provides an area under the plasma concentration curve of zoledronic acid of about 20 ng•h/ml to about 700 ng•h/ml to a human being to which the dosage form is administered.
Embodiment 141. The dosage form of embodiment 138, wherein the dosage form contains an amount of zoledronic acid in the disodium salt form that provides an area under the plasma concentration curve of zoledronic acid of about 4 ng•h/ml to about 100 ng•h/ml to a human being to which the dosage form is administered.

Embodiment 142. A dosage form comprising zoledronic acid in the disodium salt form, wherein the disodium salt form is present in a lower molar amount than would be present if the zoledronic acid were in the diacid form; and wherein the zoledronic acid in the disodium salt form has an improved bioavailability as compared to the zoledronic acid in the diacid form to the extent that the lower molar amount of the disodium salt in the dosage form does not reduce the amount of zoledronic acid delivered to the plasma of a mammal.

Embodiment 143. The dosage form of embodiment 137, 138, 139, 140, 141, or 142, wherein the dosage form is a solid.

Embodiment 144. The dosage form of embodiment 142 or 143, wherein the bioavailability of zoledronic acid in the disodium salt form is improved by at least about 10% as compared to an otherwise identical dosage form containing zoledronic acid in the diacid form.

Embodiment 145. The dosage form of embodiment 142, 143, or 144, containing at least about 20 mole% less of the disodium salt form as compared to the amount of the zoledronic acid in the diacid form that would be present if the zoledronic acid were in the diacid form.

Embodiment 146. The dosage form of embodiment 142, wherein the disodium salt form is present in an amount, on a molar basis, that has a value of about 0.9nd to about 1.1 nd, wherein:

\[ n_d = \left( \frac{b_a}{b_d} \right) n_a \]

wherein \( b_a \) is the bioavailability of the diacid form, \( b_d \) is the bioavailability of the disodium salt form, and \( n_a \) is the number of moles of the diacid form that would be present if the zoledronic acid were in the diacid form.

Embodiment 147. The dosage form of embodiment 146, wherein the disodium salt is administered in an amount that has a value of about \( n_d \).
Embodiment 148. The method of any of embodiments 1-39, 62-77, and 120-136, wherein:

only a single oral dosage form is administered; or

a first oral dosage form is administered, and a second oral dosage form is administered after the first oral dosage form, wherein the second oral dosage form is administered before the maximum pain relieving effect of the first oral dosage form is achieved, or the second oral dosage form is administered before an observable pain relieving effect is achieved.

Embodiment 149. The method of embodiment 148, wherein the second oral dosage form is administered before an observable pain relieving effect is achieved.

Embodiment 150. The method of any of embodiments 1-39, 62-77, and 120-132, wherein a first dosage form is administered, followed by administration of a second dosage form, wherein the second dosage form is administered after the maximum pain relieving effect of the first oral dosage form is achieved, and the second oral dosage form is administered while a pain relieving effect from the first oral dosage form is observable.

Embodiment 151. The method of embodiment 148, 149, or 150, wherein the second oral dosage form is administered about 24 hours to about 28 days after the first oral dosage form is administered.

Embodiment 152. The method of any of embodiments 20-39, wherein the human being is about 30 years old to about 75 years old.

Embodiment 153. The method of any of embodiments 20-39, wherein the human being is about 1 year old to about 16 years old.

Embodiment 154. The method of any of embodiments 20-39, wherein the human being is about 80 years old to about 95 years old.

Embodiment 155. The method of any of embodiments 20-39, wherein the human being has suffered from the arthritis for at least 2 months.

Embodiment 156. The method of any of embodiments 20-39, wherein the arthritis affects a knee, an elbow, a wrist, a shoulder, or a hip.
Embodiment 157. The method of any of embodiments 1-44, 62-133, and 144-156, wherein the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 1 hour before the zoledronic acid is administered.

Embodiment 158. The method of embodiment 157, wherein the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 2 hours before the zoledronic acid is administered.

Embodiment 159. The method of embodiment 158, wherein the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 4 hours before the zoledronic acid is administered.

Embodiment 160. The method of embodiment 159, wherein the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 6 hours before the zoledronic acid is administered.

Embodiment 161. The method of any of embodiments 157-160, wherein the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 30 minutes after the zoledronic acid is administered.

Embodiment 162. The method of embodiment 161, wherein the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 1 hour after the zoledronic acid is administered.

Embodiment 163. The method of embodiment 161, where in the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 2 hours after the zoledronic acid is administered.

Embodiment 164. The method, dosage form, or product, of any preceding embodiment, wherein the zoledronic acid in the oral dosage form has a 24 hour sustained plasma level factor of about 1 or higher.

Embodiment 165. The method, dosage form, or product, of any preceding embodiment, wherein the zoledronic acid in the oral dosage form has a 24 hour sustained plasma level factor that is higher than that of intravenously administered zoledronic acid.
**Embodiment 166.** The method, dosage form, or product, of any preceding embodiment, wherein the oral dosage form is a solid that has a hardness of about 5 kPa to about 20 kPa.

**Embodiment 167.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity and/or CTX serum levels.

**Embodiment 168.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 5%.

**Embodiment 169.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 10%.

**Embodiment 170.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 15%.

**Embodiment 171.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 20%.

**Embodiment 172.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 25%.

**Embodiment 173.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 30%.

**Embodiment 174.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 35%.

**Embodiment 175.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 40%.
Embodiment 176. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 45%.

Embodiment 177. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 50%.

Embodiment 178. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 55%.

Embodiment 179. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 60%.

Embodiment 180. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 60%-70%.

Embodiment 181. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity by about 70%-80%.

Embodiment 182. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 70%.

Embodiment 183. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 75%.

Embodiment 184. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity by about 80%-90%.

Embodiment 185. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 80%.

Embodiment 186. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 85%.
**Embodiment 187.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity by about 80%-85%.

**Embodiment 188.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity of at least about 90%.

**Embodiment 189.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity by about 85%-90%.

**Embodiment 190.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity by about 85%-95%.

**Embodiment 191.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity by at least about 95%.

**Embodiment 192.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity by at least about 99%.

**Embodiment 193.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases osteoclast activity by at least about 100%.

**Embodiment 194.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 5%.

**Embodiment 195.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 10%.

**Embodiment 196.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 15%.
Embodiment 198. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 20%.

Embodiment 199. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 25%.

Embodiment 200. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 30%.

Embodiment 201. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 35%.

Embodiment 202. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 40%.

Embodiment 203. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 45%.

Embodiment 204. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 50%.

Embodiment 205. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 55%.

Embodiment 206. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 60%.

Embodiment 207. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels by about 60%-70%.

Embodiment 208. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels by about 70%-80%.
**Embodiment 209.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 70%.

**Embodiment 210.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 75%.

**Embodiment 211.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 80%.

**Embodiment 212.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 85%.

**Embodiment 213.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels by about 80%-85%.

**Embodiment 214.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels of at least about 90%.

**Embodiment 215.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels by about 80%-90%.

**Embodiment 216.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels by about 85%-90%.

**Embodiment 217.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels by about 85%-95%.

**Embodiment 218.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels by about 90%-95%.

**Embodiment 219.** The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels by at least about 95%.
Embodiment 220. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels by at least about 99%.

Embodiment 221. The method, dosage form, or product, of any preceding embodiment, wherein zoledronic acid decreases CTX serum levels by at least about 100%.

[0149] Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood in all instances as indicating both the exact values as shown and as being modified by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

[0150] The terms "a," "an," "the" and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of any claim. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.

[0151] Groupings of alternative elements or embodiments disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as
modified thus fulfilling the written description of all Markush groups used in the appended claims.

[0152] Certain embodiments are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, the claims include all modifications and equivalents of the subject matter recited in the claims as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is contemplated unless otherwise indicated herein or otherwise clearly contradicted by context.

[0153] In closing, it is to be understood that the embodiments disclosed herein are illustrative of the principles of the claims. Other modifications that may be employed are within the scope of the claims. Thus, by way of example, but not of limitation, alternative embodiments may be utilized in accordance with the teachings herein. Accordingly, the claims are not limited to embodiments precisely as shown and described.
CLAIMS

What is claimed is:

1. An oral dosage form comprising zoledronic acid, wherein the oral dosage form is configured to provide a reduction of C-terminal telopeptide (CTX) serum level of at least about 50% to a human being each time the dosage form is administered.

2. An oral dosage form comprising zoledronic acid, wherein the oral dosage form is configured to provide a reduction of osteoclast activity level of at least about 50% to a human being each time the dosage form is administered.

3. The oral dosage form of claim 1 or 2, wherein the zoledronic acid is in the disodium salt form.

4. The oral dosage form of claim 3, wherein the oral bioavailability of zoledronic acid in the human being is unenhanced.

5. The oral dosage form of claim 3 or 4, wherein the oral dosage form is configured to provide an area under the plasma concentration (AUC) curve of zoledronic acid of about 4 ng·h/ml to about 2000 ng·h/ml to the human being each time the oral dosage form is administered.

6. The oral dosage form of claim 1, 2, 3, 4, or 5, wherein the oral dosage form is a solid.

7. The oral dosage form of claim 1, 2, 3, 4, 5, or 6, wherein the oral dosage form comprises about 10 mg to about 300 mg of zoledronic acid.

8. The oral dosage form of claim 7, wherein the oral dosage form comprises about 10 mg to about 50 mg of zoledronic acid.

9. The oral dosage form of claim 7, wherein the oral dosage form comprises about 20 mg to about 200 mg of zoledronic acid.

10. The oral dosage form of claim 7, wherein the oral dosage form comprises about 150 mg to about 300 mg of zoledronic acid.
11. The oral dosage form of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, wherein the oral dosage form is configured to provide a reduction of CTX serum level of at least about 55% to the human being each time the oral dosage form is administered.

12. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of at least about 60% to the human being each time the oral dosage form is administered.

13. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of about 60% to about 70% to the human being each time the oral dosage form is administered.

14. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of at least about 70% to the human being each time the oral dosage form is administered.

15. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of at least about 75% to the human being each time the oral dosage form is administered.

16. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of about 70% to about 80% to the human being each time the oral dosage form is administered.

17. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of about 80% to about 90% to the human being each time the oral dosage form is administered.

18. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of at least about 80% to the human being each time the oral dosage form is administered.

19. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of at least about 85% to the human being each time the oral dosage form is administered.
20. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of at least about 90% to the human being each time the oral dosage form is administered.

21. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of about 85% to about 95% to the human being each time the oral dosage form is administered.

22. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of about 80% to about 85% to the human being each time the oral dosage form is administered.

23. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of about 85% to about 90% to the human being each time the oral dosage form is administered.

24. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of about 90% to about 95% to the human being each time the oral dosage form is administered.

25. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of at least about 95% to the human being each time the oral dosage form is administered.

26. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of at least about 99% to the human being each time the oral dosage form is administered.

27. The oral dosage form of claim 11, wherein the oral dosage form is configured to provide a reduction of CTX serum level of at least about 100% to the human being each time the oral dosage form is administered.

28. The oral dosage form of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of at least about 55% to the human being each time the oral dosage form is administered.
29. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of at least about 60% to the human being each time the oral dosage form is administered.

30. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of about 60% to about 70% to the human being each time the oral dosage form is administered.

31. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of about 70% to about 80% to the human being each time the oral dosage form is administered.

32. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of at least about 70% to the human being each time the oral dosage form is administered.

33. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of at least about 75% to the human being each time the oral dosage form is administered.

34. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of about 80% to about 90% to the human being each time the oral dosage form is administered.

35. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of at least about 80% to the human being each time the oral dosage form is administered.

36. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of at least about 85% to the human being each time the oral dosage form is administered.

37. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of at least about 90% to the human being each time the oral dosage form is administered.
38. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of about 85% to about 95% to the human being each time the oral dosage form is administered.

39. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of about 80% to about 85% to the human being each time the oral dosage form is administered.

40. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of about 85% to about 90% to the human being each time the oral dosage form is administered.

41. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of about 90% to about 95% to the human being each time the oral dosage form is administered.

42. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of at least about 95% to the human being each time the oral dosage form is administered.

43. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of at least about 99% to the human being each time the oral dosage form is administered.

44. The oral dosage form of claim 28, wherein the oral dosage form is configured to provide a reduction of osteoclast activity of at least about 100% to the human being each time the oral dosage form is administered.

45. A method of treating pain, comprising administering an oral dosage form of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 to a human being in need thereof.

46. The method of claim 45, wherein the zoledronic acid is used to treat an inflammatory condition.

47. The method of claim 45, wherein the zoledronic acid is used to treat arthritis.
48. The method of claim 45, wherein the zoledronic acid is used to treat complex regional pain syndrome (CRPS).

49. The method of claim 45, wherein the zoledronic acid is used to treat low back pain.
FIG. 1
FIG. 2A

<table>
<thead>
<tr>
<th>Drug</th>
<th>% Reversal of Arthritis Pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zoledronic acid 54 mg/m²</td>
<td>30%</td>
</tr>
<tr>
<td>Zoledronic acid 360 mg/m²</td>
<td>50%</td>
</tr>
</tbody>
</table>
FIG. 3
FIG. 4
FIG. 7
FIG. 8
FIG. 9
**INTERNATIONAL SEARCH REPORT**

**International application No.**

PCT/US 2016/028807

**A. CLASSIFICATION OF SUBJECT MATTER**

A61K 31/663 (2006.01)
A61P 19/02 (2006.01)
A61P 29/00 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

A61K 31/00, 31/66, 31/662, 31/663, A61P 19/00, 19/02, 29/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Esp@cenet, PubMed, EAPO, RUPAT, PatSearch (RUPTO internal)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 2010/0215743 A1 (LEONARD THOMAS W.) 26.08.2010, paragraphs [0007]-[0009], [0025], [0026], [0054], [0055], [0057]. example 2, fig.1</td>
<td>1-4</td>
</tr>
<tr>
<td>X</td>
<td>US 2015/0051175 A1 (ANTECIP BIOVENTURES II LLC) 19.02.2015, abstract, paragraphs [0008], [0032]. claims</td>
<td>1-4, 45-49</td>
</tr>
</tbody>
</table>

* Further documents are listed in the continuation of Box C.  

See patent family annex.

* Special categories of cited documents:

  "A" document defining the general state of the art which is not considered to be of particular relevance

  "E" earlier document but published on or after the international filing date

  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

  "O" document referring to an oral disclosure, use, exhibition or other means

  "P" document published prior to the international filing date but later than the priority date claimed

  "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

  "&" document member of the same patent family

**Date of the actual completion of the international search**

29 June 2016 (29.06.2016)

**Date of mailing of the international search report**

11 August 2016 (11.08.2016)

**Name and mailing address of the ISA/RU:**

Federal Institute of Industrial Property, Berezhkovskaya nab., 30-1, Moscow, G-59, GSP-3, Russia, 125993

Facsimile No: (8-495) 531-63-18, (8-499) 243-33-37

Authorized officer

V.Usachova

Telephone No. 495 531 65 15

Form PCT/ISA/210 (second sheet) (January 2015)
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☑ Claims Nos.: 5-44
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.